Overall Survival in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with >30% Bone Marrow Blasts Treated with Azacitidine By Cytogenetic Risk Status: Results of the AZA-AML-001 Study
Explore this paper's citation graph
Summary
The phase 3, multicenter, randomized, open-label AZA-AML-001 trial showed azacitidine Tx in older pts with newly diagnosed AML prolonged median OS by ~4 mos vs conventional care regimens (CCR) and improved 1-year survival (46.5% vs 34.2%) and Cytogenetic risk was balanced between Tx groups.
- Type
- article
- Published
- 2014-12-06
- Cited by
- 11
- References
- 0
- OpenAlex
- https://openalex.org/W1040989942
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:68849049
Keywords
Medicine, Azacitidine, Internal medicine, Myeloid leukemia, Oncology
References
No references recorded for this paper.
Cited by
- Management of Newly Diagnosed Acute Myeloid Leukemia in the Elderly: Current Strategies and Future Directions
- ASH 2014 update: Myelodysplastic syndromes and acute myeloid leukemia
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.
- Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group
- Hypomethylating Agents as a Therapy for AML
- Azacitidine in adult patients with acute myeloid leukemia.
- Effectiveness and Safety of Therapeutic Regimens for Elderly Patients With Acute Myeloid Leukemia: A Systematic Literature Review
- Treatment of older patients with acute myeloid leukemia (AML): revised Canadian consensus guidelines.
- Low-Dose Cytarabine versus Best Supportive Care for Patients with Acute Myeloid Leukaemia Unfit for the Standard of Care: Egyptian Centre Experience
- Acute myeloid leukemia
- Acute myeloid leukemia.
- Treatment of Newly Diagnosed AML in Unfit Patients
Related papers
- Concise drug review: azacitidine and decitabine.
- Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine
- Use of Azacitidine or Decitabine for the Up-Front Setting in Acute Myeloid Leukaemia: A Systematic Review and Meta-Analysis
- Improved Responses with Azacitidine Compared to Decitabine in Patients with Acute Myeloid Leukemia in Patients ≥70 with Poor-Risk Cytogenetics
- The euphoria of hypomethylating agents in MDS and AML: is it justified?
- Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine
- Comparison between 5-day decitabine and 7-day azacitidine for lower-risk myelodysplastic syndromes with poor prognostic features: a retrospective multicentre cohort study
- Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia
- CLO22-037: Tumor Lysis Syndrome and Infectious Complications During Induction With Venetoclax Combined With Azacitidine or Decitabine in Patients With Acute Myeloid Leukemia
- Hypomethylating agents in the treatment of myelodysplastic syndromes and myeloid leukemia.